Live Chat

Trade Vir Biotechnology VIR

VirBiotechnology live chart

instrument_fundamentals

Weekly Search
Weekly
Daily
date Close change Change (%) instr__open High Low

instr__news

Webhose 2024 Dec 21, 08:25

State Street Corp Has $42.14 Million Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

Vir Biotechnology Inc
Webhose 2024 Dec 20, 09:11

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Y Intercept Hong Kong Ltd

Vir Biotechnology Inc
Webhose 2024 Dec 16, 00:22

Vir Biotechnology's SWOT analysis: stock poised for growth amid hepatitis breakthroughs By Investing.com

Vir Biotechnology Inc
Webhose 2024 Dec 12, 13:22

Vir Biotechnology's drugs receive FDA and EMA nods By Investing.com

Vir Biotechnology Inc
Webhose 2024 Dec 12, 08:12

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Vir Biotechnology Inc
Webhose 2024 Dec 11, 08:05

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Charles Schwab Investment Management Inc.

Vir Biotechnology Inc
Webhose 2024 Dec 02, 21:50

Vir Biotechnology Trades Higher in Sympathy with Janux Therapeutics By Investing.com

Vir Biotechnology Inc
Webhose 2024 Nov 29, 08:11

Victory Capital Management Inc. Acquires 15,696 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Vir Biotechnology Inc
Webhose 2024 Nov 26, 14:30

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs | Morningstar

Vir Biotechnology Inc
Webhose 2024 Nov 25, 14:30

Company Website: https://www.vir.bio SAN FRANCISCO -- (Bus

Vir Biotechnology Inc
Webhose 2024 Nov 25, 14:26

Vir Biotechnology's SWOT analysis: stock poised for growth amid clinical progress By Investing.com

Vir Biotechnology Inc

Markets.com news

Info

Spread

0.05

Spread (%)

0.6623 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Tuesday

14:31 - 20:59

Monday

14:31-20:59

Wednesday

14:31-20:59

Thursday

14:31-20:59

Friday

14:31-20:59

instr__analysis_statistics

instr__open

---

instr__close

---

instr__52week_range

--- – ---

instr__market_cap

1010864832

instr__shares_outstand

137720000

instr__earnings_date

0000-00-00

instr__dividend_date

instr__ex_dividend_date

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

instr__eps

-3.93

instrument_learn_more

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

related_instruments

view_all_instruments
Trustpilot
Live Chat